Ware, Michael B.
Zaidi, Mohammad Y.
Yang, Jennifer
Turgeon, Michael K.
Krasinskas, Alyssa
Mace, Thomas A.
Keenan, Kaitlin
Farren, Matthew R.
Ruggieri, Amanda N.
Li, Yiman
Zhang, Chao
Chen, Zhengjia
Young, Gregory S.
Elnaggar, Omar
Che, Zheng
Maithel, Shishir K.
Bekaii-Saab, Tanios
El-Rayes, Bassel
Lesinski, Gregory B. http://orcid.org/0000-0002-8787-7678
Funding for this research was provided by:
U.S. Department of Health & Human Services | National Institutes of Health (P30CA138292, 1R01 CA228414-01, P30CA16058, T32CA090223)
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
U.S. Department of Health & Human Services | National Institutes of Health
Philanthropic fund from a private donor to The Ohio State University
Article History
Received: 20 April 2020
Revised: 26 June 2020
Accepted: 17 July 2020
First Online: 4 August 2020
Ethics approval and consent to participate
: All studies on human tissue were conducted under Institutional Review Board-approved protocol at Winship Cancer Institute of Emory University. All patients consented to the collection and inclusion of samples used in these studies. All research herein was conducted in accordance with the Declaration of Helsinki.
: Not applicable.
: The data sets generated during and/or analysed during the current study is available from the corresponding author on reasonable request.
: Dr. Lesinski has consulted for ProDa Biotech, LLC and received compensation. Dr. Lesinski has received research funding through a sponsored research agreement between Emory University and Merck and Co., Inc., Bristol-Myers Squibb, Inc., Boerhinger-Ingleheim, Inc., and Vaccinex, Inc. Dr. El-Rayes has consulted for Ipsen, Merck and Co., BayerAstraZeneca, and Bristol-Myers Squibb, Inc. and has been a speaker for Lexicon, Inc. Dr. El-Rayes serves as a consultant to Merck and Co. and receives compensation for these services. The terms of this arrangement have been reviewed and approved by Emory University in accordance with its conflict of interest policies. Dr. El-Rayes has received research funding through a sponsored research agreement between Emory University and Bristol-Myers Squibb, Boston Biomedical, Novartis, Merck and Co, Bayer, Exelixis, Pfizer, AstraZeneca/Medimmune, Incyte, and EUSA.
: Research reported in this publication was supported under award number P30CA138292 and 1R01 CA228414-01. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. This work was also supported by funding from The National Institutes of Health, P30CA16058, T32CA090223, and from the William Hall Fund for Liver and Pancreatic Cancer Research.